نتایج جستجو برای: hiv vaccine

تعداد نتایج: 309384  

Journal: :Vaccine 2013
Michael P Cameron Peter A Newman Surachet Roungprakhon Riccardo Scarpa

This paper estimates the marginal willingness-to-pay for attributes of a hypothetical HIV vaccine using discrete choice modeling. We use primary data from 326 respondents from Bangkok and Chiang Mai, Thailand, in 2008-2009, selected using purposive, venue-based sampling across two strata. Participants completed a structured questionnaire and full rank discrete choice modeling task administered ...

Journal: :Journal of immunology 2003
Cara C Wilson Denise McKinney Michelle Anders Samantha MaWhinney Jeri Forster Claire Crimi Scott Southwood Alessandro Sette Robert Chesnut Mark J Newman Brian D Livingston

Epitope-based vaccines designed to induce CTL responses specific for HIV-1 are being developed as a means for addressing vaccine potency and viral heterogeneity. We identified a set of 21 HLA-A2, HLA-A3, and HLA-B7 restricted supertype epitopes from conserved regions of HIV-1 to develop such a vaccine. Based on peptide-binding studies and phenotypic frequencies of HLA-A2, HLA-A3, and HLA-B7 all...

2014
Yuan Dong Xiaoxing Shen Ruizhang Guo Baochi Liu Lingyan Zhu Jing Wang Linxia Zhang Jun Sun Xiaoyan Zhang Jianqing Xu

BACKGROUND More and more HIV therapeutic vaccines will enter clinical trials; however, little is known about the willingness to participate (WTP) in HIV therapeutic vaccine trials among HIV-positive individuals. OBJECTIVE To investigate the WTP in HIV therapeutic vaccine trials among Chinese HIV-infected patients. METHODS We conducted a cross-sectional survey on HIV-positive inpatients and ...

2017
Bikash Sahay Cuong Q. Nguyen Janet K. Yamamoto

Despite major advances in antiretroviral therapy against HIV-1, an effective HIV vaccine is urgently required to reduce the number of new cases of HIV infections in the world. Vaccines are the ultimate tool in the medical arsenal to control and prevent the spread of infectious diseases such as HIV/AIDS. Several failed phase-IIb to -III clinical vaccine trials against HIV-1 in the past generated...

Journal: :Journal of acquired immune deficiency syndromes 2006
Surender Khurana James Needham Susan Park Bonnie Mathieson Michael P Busch George Nemo Phillipe Nyambi Susan Zolla-Pazner Suman Laal Joseph Mulenga Elwyn Chomba Eric Hunter Susan Allen James McIntyre Indira Hewlett Sherwin Lee Shixing Tang Elliot Cowan Chris Beyrer Marcus Altfeld Xu G Yu Anatole Tounkara Ousmane Koita Anatoli Kamali Nga Nguyen Barney S Graham Deborah Todd Peter Mugenyi Omu Anzala Eduard Sanders Nzeera Ketter Patricia Fast Hana Golding

Because increasing numbers of HIV vaccine candidates are being tested globally, it is essential to differentiate vaccine- from virus-induced antibodies. Most of the currently tested vaccines contain multiple viral components. As a result, many vaccine recipients give positive results in FDA-licensed HIV serodetection tests. We have identified conserved sequences in Env-gp41 and Gag-p6, which ar...

Journal: :The New England journal of medicine 2009
Supachai Rerks-Ngarm Punnee Pitisuttithum Sorachai Nitayaphan Jaranit Kaewkungwal Joseph Chiu Robert Paris Nakorn Premsri Chawetsan Namwat Mark de Souza Elizabeth Adams Michael Benenson Sanjay Gurunathan Jim Tartaglia John G McNeil Donald P Francis Donald Stablein Deborah L Birx Supamit Chunsuttiwat Chirasak Khamboonruang Prasert Thongcharoen Merlin L Robb Nelson L Michael Prayura Kunasol Jerome H Kim

BACKGROUND The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. METHODS In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombina...

Journal: :Journal of Virology 2021

In this placebo-controlled phase II randomized clinical trial, we evaluated the safety and immunogenicity of a therapeutic prime-boost vaccine strategy using recombinant DNA (GTU-MultiHIV B clade) followed by boost vaccination with lipopeptide (HIV-LIPO-5) in HIV-infected patients on combined antiretroviral therapy. We show here that is well tolerated, consistently previous studies HIV-1-infect...

Journal: :The Journal of infectious diseases 2002
Mary A Marovich John R Mascola Michael A Eller Mark K Louder Pierre A Caudrelier Raphaelle El-Habib Silvia Ratto-Kim Josephine H Cox Jeffrey R Currier Bruce L Levine Carl H June Wendy B Bernstein Merlin L Robb Beatrice Schuler-Thurner Ralph M Steinman Deborah L Birx Sarah Schlesinger-Frankel

Preclinical data are reported that support a human immunodeficiency virus (HIV) vaccine strategy using recombinant canarypox-HIV vectors (ALVAC-HIV) to load human dendritic cells (DCs) with HIV antigens. Clinical-grade DCs were infected with good manufacturing practice-grade ALVAC-HIV vaccine constructs. ALVAC infection, HIV gene expression, and DC viability and function were monitored by use o...

Journal: :Human vaccines 2011
Leia Wren Stephen J Kent

The partial efficacy of the recent HIV-1 vaccine trial in Thailand has rejuvenated the HIV vaccine field. There are now clear opportunities to dissect the potential correlates of protection against HIV-1. Comparisons of three major HIV-1 vaccine strategies used in human efficacy trials to date highlight a possible role for antibody-dependent cellular cytotoxicty (ADCC), rather than cytotoxic T ...

2017
Sharise Richardson Pich Seekaew Beryl Koblin Tasha Vazquez Vijay Nandi Hong-Van Tieu

BACKGROUND Black men who have sex with men (MSM), and Transwomen (TW) shoulder disproportionate burden of HIV. However, they are unrepresented in HIV vaccine trials. We investigated the perceptions of that factors associated with HIV vaccine trials participation among Black MSM and TW in New York. METHODS Self-administered online questionnaires were administered to 18-29 years of NYC resident...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید